What trials demonstrate canakinumab biosimilar's efficacy in cardiovascular disease?

Can a canakinumab biosimilar stand in for the original drug in heart‑attack prevention?
No cardiovascular trials have been published for any canakinumab biosimilar to date. All evidence that the drug reduces major adverse cardiovascular events (MACE) comes from the original canakinumab product, tested in the CANTOS study.

Which studies proved the parent drug works for heart disease?
The pivotal CANTOS (Canakinumab Anti‑Inflammatory Thrombosis Outcomes Study) enrolled 10,061 post‑myocardial‑infarction patients with high hs‑CRP. Over 3.7 years, canakinumab cut the risk of non‑fatal MI, non‑fatal stroke, and cardiovascular death by 15% compared with placebo, while lowering CRP by 80% [1].

What endpoints did CANTOS track and how were they measured?
CANTOS used a composite primary endpoint of MACE, defined as cardiovascular death, non‑fatal MI, or non‑fatal stroke. Secondary endpoints included all‑cause mortality, revascularization, and CRP decline. The drug was dosed 150 mg subcutaneously every 3 months, with safety monitored through adverse‑event reporting.

Have any biosimilar trials included cardiovascular outcomes as safety or exploratory endpoints?
Phase I/II biosimilarity studies have focused on rheumatologic conditions—rheumatoid arthritis, juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis—to confirm comparable pharmacokinetics, immunogenicity, and efficacy. These trials did not evaluate cardiovascular endpoints; any cardiovascular data were limited to background risk assessment.

What does regulatory guidance say about using biosimilars for cardiovascular indications?
Both the FDA and EMA allow biosimilar approval for the same indications as the reference product only when the biosimilar has demonstrated equivalence in the original therapeutic area. Because the only proven cardiovascular benefit of canakinumab comes from CANTOS, a biosimilar would need to reproduce that efficacy in a dedicated cardiovascular trial to gain approval for this indication [2][3].

When might we see a biosimilar cardiovascular trial?
Developers would need to design a phase III trial that mirrors CANTOS’s design—enrolling post‑MI patients with elevated hs‑CRP and monitoring MACE over a multi‑year period. No such study has been announced or registered yet, so availability of cardiovascular data for a biosimilar is not expected in the near term.

Bottom line
Canakinumab’s cardiovascular benefit is established only for the reference product via the CANTOS trial. Biosimilar candidates have not yet completed cardiovascular efficacy studies, so no trials currently demonstrate that a canakinumab biosimilar can replicate the parent drug’s heart‑attack‑reducing effects.